Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21845248 | 0.85 | PARP1 (0.49) | PTGS1PTGS2ALOX5BRD4SCN4A | |
| SCHEMBL21828706 | 0.84 | HNF4A (0.44) | PTGS1PTGS2BRD4SCN4ASCN9A | |
| SCHEMBL22235420 | 0.80 | PTGS1 (0.38) | PTGS1PTGS2ALOX5BRD4ALDH1A1 | |
| SCHEMBL31566429 | 0.80 | PTGS1 (0.38) | PTGS1PTGS2ALOX5BRD4ALDH1A1 | |
| SCHEMBL9056358 | 0.78 | PTGS1 (0.36) | PTGS1PTGS2BRD4ALDH1A1ALOX15 | |
| SCHEMBL3456244 | 0.74 | HPGD (0.52) | PTGS1PTGS2ALOX5ALDH1A1ALOX15 | |
| SCHEMBL12678908 | 0.72 | PTGS1 (0.38) | PTGS1PTGS2ALOX5 | |
| SCHEMBL3307612 | 0.72 | PTGS1 (0.38) | PTGS1PTGS2ALOX5ALDH1A1MEN1 | |
| SCHEMBL3456240 | 0.72 | NPC1 (0.46) | MEN1KMT2A | |
| SCHEMBL21845225 | 0.72 | PARP1 (0.38) | PTGS1PTGS2ALOX5ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601291-B1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-110831945-B | 11, 13-modified saxitoxins for the treatment of pain | 赛特温治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220259218-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-08-18 | — | — | US | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| CN-110831945-A | 11, 13-modified saxitoxins for the treatment of pain | 赛特温治疗公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-3601291-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | Siteone Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183781-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | PTGS1 843/4885PTGS2 1392/4885ALOX5 2930/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | PTGS1 843/4885PTGS2 1392/4885ALOX5 2930/4885 |
| US-20220259218-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | PTGS1 843/4885PTGS2 1392/4885ALOX5 2930/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | PTGS1 843/4885PTGS2 1392/4885ALOX5 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.